Mizuho Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $8

Benzinga Newsdesk www.benzinga.com Positive 61.6%

Neg 0% Neu 0% Pos 61.6%

Mizuho analyst Salim Syed initiates coverage on Century Therapeutics (NASDAQ:IPSC) with a Outperform rating and announces Price Target of $8.